Communication Affichée: Poster tour 2
Le 14/10/2021 de 17:30 à 18:00
Effets précoces et à long terme d'injection unique par toxine botulique A évalués par élastosonographie chez les enfants atteints de paralysie cérébrale
Soumaya Boudokhane (Monastir, Tunisie), Houda Migaou (Monastir, Tunisie), Amine Kalai (Monastir, Tunisie), Ons Borgi (Monastir, Tunisie), Meriem Frigui (Monastir, Tunisie), Mezri Maatouk (Monastir, Tunisie), Badii Hmida (Monastir, Tunisie), Zohra Ben Salah Frih (Monastir, Tunisie)
Objective : Evaluate the early and long-term effect of single event injection of BTA in gastrocnemius muscle (GCM) using ultrasoud elastography (UE).
Material / Patients and Methods : Ambulant children with spastic CP, who will receive first time injection of BTA were enrolled in the study. Injection was administered into GCM of 15 children. Clinical assessments before injection, 1-2-3-4 weeks, 3 and 6 months following each injection included range of motion (ROM) and the Modified Ashworth Scale (MAS). Spaticity was also assessed with the UE at the same time and the strain index value (SIV) was calculated.
Results : The mean age was 6.8 years ± 3.85. Nineteen lower limbs were injected by BTA for the first time. The average MAS score was 2.57 +/- 1.07 and the average SIV was 2.15 +/- 0.41 before BTA injection. After BTA injection a significant improvements were observed in MAS grades, SIV and dorsiflexion ankle passive and active goniometric measurements after 2, 3 ,4 weeks and 3 months (p < 0.05).A significant correlation was found between MAS and SIV before BTA injection. This correlation persisted significantly up to 6 months after BTA injection.
Discussion - Conclusion : Many of the steps in the action of the BTA are well understood, the factors underlying the timing of these steps are less so. In our study, the effect of the BTA on the GCM injected for the first time was observed from the second week and persisted up to 3 months and this was observed both by MAS and by the UE.
Keywords : spasticity, cerebral palsy, botulinium toxin, early and long-term follow-up